BioVie Reports Positive Phase 2 Data for Bezisterim in Long COVID Treatment

Key Facts

Amid the ongoing global efforts to address the lingering health impacts of the pandemic, BioVie Inc. has announced promising clinical trial results. According to reports, its drug Bezisterim demonstrated statistically significant benefits in improving fatigue and cognitive impairment in patients suffering from Long COVID. The Phase 2 ADDRESS-LC trial specifically targeted neurological symptoms, including post-exertional malaise and memory difficulties, which remain a major challenge for millions of patients.

These positive results serve as a significant catalyst for the micro-cap biotech firm, as Phase 2 data often dictates the future trajectory of clinical development. Per market data, the trial's success in specific pre-specified subgroups reinforces the biological hypothesis that targeting innate inflammation can alleviate chronic symptoms. The findings are particularly relevant given the high prevalence of daily life limitations reported by those living with persistent post-viral conditions.

Regarding market performance, BIVI stood at $2.05 (close September 14, 2026), having traded between a day low of $1.88 and a high of $2.12. With no major sector-specific catalysts in the upcoming economic calendar, investors will likely focus on the company's ability to replicate these findings in larger-scale trials and its capacity to secure the necessary capital for further clinical advancement.